Global Blood Therapeutics (GBT): “Overweight” Rating was Reconfirmed by Research Analysts at Cantor Fitzgerald; with PT of $96.

June 29, 2018 - By Gwen Gough

Global Blood Therapeutics, Inc. (NASDAQ:GBT) Corporate Logo

Reiterated Global Blood Therapeutics (GBT) Rating.

On 28 June Cantor Fitzgerald have a $96 target on Global Blood Therapeutics (GBT). A upside potential of 107.79 % have this target. The $2.39B market cap company have “Overweight” stock rating revealed to investors in an analyst report.

Global Blood Therapeutics, Inc. (NASDAQ:GBT) Ratings Coverage

In total 10 analysts cover Global Blood Therapeutics (GBT). “Buy” rating has 9, “Sell” are 0, while 1 are “Hold”. (GBT) has 90% bullish analysts. 25 are the (GBT)’s ratings reports on Jun 29, 2018 according to StockzIntelligence Inc. On Thursday, June 28 the stock has “Buy” rating by Nomura. On Sunday, June 17 the rating was maintained by Oppenheimer with “Buy”. On Thursday, January 11 the stock has “Buy” rating by H.C. Wainwright. On Tuesday, March 6 the company was maintained by Morgan Stanley. In Thursday, January 11 report Cowen & Co maintained it with “Buy” rating and $83.0 target. On Wednesday, March 14 Wedbush maintained Global Blood Therapeutics, Inc. (NASDAQ:GBT) rating. Wedbush has “Buy” rating and $73.0 target. On Thursday, January 11 the stock has “Buy” rating by Oppenheimer. On Friday, June 15 the stock has “Buy” rating by Cantor Fitzgerald. On Monday, June 18 the stock of Global Blood Therapeutics, Inc. (NASDAQ:GBT) earned “Buy” rating by Wedbush. On Tuesday, March 20 the stock of Global Blood Therapeutics, Inc. (NASDAQ:GBT) has “Buy” rating given by Oppenheimer.

GBT hit $46.2 during the last trading session after $1.25 change.Global Blood Therapeutics, Inc. has volume of 756,397 shares. Since June 29, 2017 GBT has risen 60.31% and is uptrending. GBT outperformed by 47.74% the S&P500.

On August, 6 WallStreet awaited Global Blood Therapeutics, Inc. (NASDAQ:GBT)’s earnings release, RTT reports. Analysts predict $-0.87 earnings per share. That’s $0.32 down or 58.18 % from 2017’s earnings of $-0.55. 0.00 % EPS growth is what Wall Street’s predicts after $-0.87 reported EPS previous quarter.

Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood disorders.The firm is worth $2.39 billion. The Company’s lead product candidate is voxelotor, an oral once-daily therapy that modulates hemoglobin's affinity for oxygen, which is in Phase III clinical trials in adult and adolescent patients with sickle cell disease .Currently it has negative earnings. The firm is also involved in evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trials of adolescent and pediatric patients with SCD; and other research and development activities that are in pre-clinical phase.

For more Global Blood Therapeutics, Inc. (NASDAQ:GBT) news brought out briefly go to:,,, or The titles are as follows: “40 Stocks Moving In Wednesday’s Mid-Day Session” brought out on June 27, 2018, “Why Sangamo Therapeutics and bluebird bio Slipped Lower Today” on June 27, 2018, “Global Blood Therapeutics (GBT) Reports Statistically Significant Results from Part A of the Phase 3 HOPE Study of …” with a publish date: June 27, 2018, “42 Biggest Movers From Yesterday” and the last “GBT Announces Positive Top-line Data from Part A of the Phase 3 HOPE Study of Voxelotor in Sickle Cell Disease” with publication date: June 27, 2018.

Global Blood Therapeutics, Inc. (NASDAQ:GBT) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: